Navigation Links
Vivakor Confirms Record Date of Stock Dividend
Date:12/4/2009

CORALVILLE, Iowa, Dec. 4 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today confirmed that its shareholders of record on December 1, 2009 will receive the dividend of shares of common stock of HealthAmerica, Inc. that was previously approved by Vivakor's Board of Directors. HealthAmerica is a private Nevada corporation of which Vivakor owned approximately 84% of the outstanding common shares on the record date. The distribution date is still expected to be December 9, 2009. Each Vivakor shareholder will be entitled to receive one share of HealthAmerica common stock for each share of Vivakor common stock beneficially owned on December 1, 2009. After the dividend distribution, Vivakor will continue to own approximately 62% of the outstanding common stock of HealthAmerica.

Vivakor shareholders will not be required to take any action to receive the HealthAmerica common shares on the distribution date.

About Vivakor, Inc.

Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at www.vivakor.com.

About HealthAmerica, Inc.

HealthAmerica is developing a patented, FDA 510(k) cleared, technology (VIVASlices(TM) that is expected to enhance the resolution of images resulting from MRI. The underlying algorithm may also be useful in determining blood flow velocity measures in imaged tissues, which would be valuable in accessing areas of blood flow constriction from plaques or other hematologic deposits. This information could help physicians better diagnose, predict and assess stroke and related diseases involving blood flow obstruction.

At the end of 2000, there were approximately 9,500 MRI (magnetic resonance imaging) systems installed worldwide. While changes in medical reimbursements have slowed the sale of new machines, there is an increased demand for improved efficiency (i.e. accelerated patient throughput) from current systems. Additionally, intense competition between various medical facilities and the rapid distribution of new advances in imaging (such as MR angiographies, which allow evaluation of blood vessels without any invasive procedure) puts additional pressure on MRI because increased image quality requires additional time. Thus there is a huge need for an application like VIVASlices that can improve both throughput and image quality.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's and HealthAmerica's products and markets. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.


    Contact:
    Vivakor, Inc.
    Matt Nicosia, 319-625-2172
    mnicosia@vivakor.com

SOURCE Vivakor, Inc.


'/>"/>
SOURCE Vivakor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vivakor, Inc. Announces Stock Dividend
2. New study confirms exotic electric properties of graphene
3. Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products
4. Analysis confirms that nano-related research has strong multidisciplinary roots
5. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
6. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
7. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
8. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
9. NIH News Confirms Trend in Stem Cell Storage Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
10. GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
11. Mylan Confirms Four First-to-File Challenges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
Breaking Biology News(10 mins):